International Assets Investment Management LLC Purchases 58,299 Shares of Repligen Co. (NASDAQ:RGEN)

International Assets Investment Management LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN) by 18,449.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 58,615 shares of the biotechnology company’s stock after purchasing an additional 58,299 shares during the period. International Assets Investment Management LLC’s holdings in Repligen were worth $10,539,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in shares of Repligen by 70.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 910 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 377 shares in the last quarter. Asset Management One Co. Ltd. increased its holdings in Repligen by 9.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 21,425 shares of the biotechnology company’s stock valued at $3,971,000 after buying an additional 1,888 shares during the period. Arizona State Retirement System raised its stake in Repligen by 0.9% in the fourth quarter. Arizona State Retirement System now owns 14,558 shares of the biotechnology company’s stock worth $2,618,000 after buying an additional 127 shares in the last quarter. Ballentine Partners LLC lifted its holdings in Repligen by 49.2% during the fourth quarter. Ballentine Partners LLC now owns 2,651 shares of the biotechnology company’s stock worth $477,000 after buying an additional 874 shares during the period. Finally, Trust Point Inc. purchased a new stake in Repligen during the fourth quarter worth $766,000. 97.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 25,597 shares of company stock valued at $5,039,532. Insiders own 1.20% of the company’s stock.

Repligen Trading Up 0.4 %

Shares of NASDAQ:RGEN opened at $167.05 on Monday. The business’s 50-day moving average is $180.81 and its 200 day moving average is $174.32. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.75. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The firm has a market capitalization of $9.33 billion, a P/E ratio of 668.23, a P/E/G ratio of 5.46 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to analysts’ expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. Repligen’s revenue was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 EPS. On average, research analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of several recent research reports. KeyCorp boosted their price target on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Stifel Nicolaus lifted their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $197.75.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.